Use of a bispecific anti-tgfbetar2 / pd-1 antibody.

Abstract

This disclosure describes a bispecific antibody directed against human PD-1 protein and human transforming growth factor receptor 2 (TGFBR2) for use in the treatment of disorders such as non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (SCCHN), cervical squamous carcinoma and endocervical adenocarcinoma (CESC), ovarian cancer, breast cancer, bladder cancer, renal cell carcinoma, melanoma, gastric adenocarcinoma, esophageal cancer, gastroesophageal adenocarcinoma, malignant pleural mesothelioma, pancreatic adenocarcinoma, and colorectal cancer (CRC).